1.Post-infectious Functional Dyspepsia - A Novel Disease Entity among Functional Gastrointestinal Disorders - Relation to Helicobacter pylori Infection? (Neurogastroenterol Motil 2009;21:832-e56).
Journal of Neurogastroenterology and Motility 2010;16(1):97-98
No abstract available.
Dyspepsia
;
Gastrointestinal Diseases
;
Helicobacter
;
Helicobacter pylori
2.Overlap Syndrome of Functional Dyspepsia and Irritable Bowel Syndrome - Are Both Diseases Mutually Exclusive?.
Hidekazu SUZUKI ; Toshifumi HIBI
Journal of Neurogastroenterology and Motility 2011;17(4):360-365
Among functional gastrointestinal (GI) disorders, functional dyspepsia (FD) and irritable bowel syndrome (IBS) are important to public health around the world and are frequently encountered in general practice. Upper GI symptoms such as heartburn, postprandial fullness, early satiety, epigastric pain or burning and lower GI symptoms such as constipation and diarrhea often coexist. Although the prevalence of FD-IBS overlap would be influenced by the selection of the study population, the overlap rate of FD-IBS could be in the range of 11%-27%. Specifically, FD-IBS overlap is associated with more severe symptoms than FD alone or IBS alone. Since clinical overlap, especially FD-IBS overlap, is very common, the 2 syndromes should not be treated in a mutually exclusive fashion.
Burns
;
Constipation
;
Diarrhea
;
Dyspepsia
;
General Practice
;
Heartburn
;
Irritable Bowel Syndrome
;
Prevalence
;
Public Health
3.Are Solifenacin and Ramosetron Really Ideal to Treat Irritable Bowel Syndrome?: Author's Reply.
Hidekazu SUZUKI ; Juntaro MATSUZAKI
Journal of Neurogastroenterology and Motility 2012;18(4):459-459
No abstract available.
Benzimidazoles
;
Quinuclidines
;
Tetrahydroisoquinolines
;
Solifenacin Succinate
4.The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia.
Journal of Neurogastroenterology and Motility 2017;23(3):325-333
The Rome criteria were amended as Rome IV. For functional esophageal disorders, the exclusion criteria have been more specifically revised based on further understanding of other esophageal disorders, including eosinophilic esophagitis and spastic and hypercontractile motor disorders. Another revised point is the more restrictive definition of gastroesophageal reflux disease, indicating that sensitivity to a physiological reflux burden may be placed more firmly within the functional group. For functional dyspepsia (FD), only minor changes were introduced, mainly to improve specificity. Among the major symptoms of FD, not only postprandial fullness, but also epigastric pain, epigastric burning, and early satiation should be “bothersome.” Investigation on the effect of meal ingestion on symptom generation has indicated that not only postprandial fullness and early satiety, but also epigastric pain, epigastric burning sensation and nausea (not vomiting) may increase after meals. Helicobacter pylori infection is considered a possible cause of dyspepsia if successful eradication leads to sustained resolution of symptoms for more than 6 months, and such status can be termed as “H. pylori–associated dyspepsia.” Prompt esophagogastroduodenoscopy and H. pylori testing and treatment would be more beneficial, especially in Asia, which has a high prevalence of gastric cancer. Acotiamide, tandospirone, and rikkunshito are the newly listed as treatment options for FD. For further therapeutic development, clinical studies based on the strict Rome IV criteria should be performed.
Asia*
;
Burns
;
Dyspepsia
;
Eating
;
Endoscopy, Digestive System
;
Eosinophilic Esophagitis
;
Eructation
;
Gastroesophageal Reflux
;
Heartburn
;
Helicobacter pylori
;
Meals
;
Motor Disorders
;
Muscle Spasticity
;
Nausea
;
Prevalence
;
Satiation
;
Sensation
;
Sensitivity and Specificity
;
Stomach Neoplasms
5.Precision Medicine Approaches to Prevent Gastric Cancer
Juntaro MATSUZAKI ; Hitoshi TSUGAWA ; Hidekazu SUZUKI
Gut and Liver 2021;15(1):3-12
Gastric cancer remains one of the most common causes of cancer-related death worldwide, although the incidence is declining gradually. The primary risk factor for gastric cancer is Helicobacter pylori infection. The Kyoto global consensus report recommends eradication of H. pylori in all infected patients. However, because it is difficult to stratify the risk of carcinogenesis among patients with a history of H. pylori infection, annual endoscopic surveillance is performed for everyone after eradication. This review summarizes the current approaches used to screen for novel molecules that could assist in the diagnosis of gastric cancer and reduce mortality. Most well-studied molecules are tissue protein biomarkers expressed by the gastric epithelium and associated with metaplasia-dysplasia-carcinoma sequences. Other strategies focus on the origin of cancer stem cell-related markers, such as CD44, and immune reaction-related markers, such as matrix metallopeptidases. Noninvasive methods such as blood-based approaches are more attractive. Serum pepsinogen levels predict the severity of gastric mucosal atrophy before H. pylori eradication, whereas plasma ghrelin levels are associated with atrophy even after eradication.Cell-free DNAs and RNAs are attractive tools for the early detection of cancer. These ideas could lead to the development of more personalized strategies for cancer prevention based on cuttingedge technologies.
6.Ghrelin - A Novel Appetite-stimulating Hormone Which Also Affects Gastrointestinal Functions.
Hidekazu SUZUKI ; Tatsuhiro MASAOKA ; Toshifumi HIBI
The Korean Journal of Gastroenterology 2006;48(2):82-88
Ghrelin, a novel gastrointestinal peptide with 28 amino acids, is secreted from the A-like cells of the gastric fundus. This peptide hormone does not only promote the release of growth hormone, but also stimulates food intake, gastric motility and cardiac output. Increased plasma ghrelin level has been reported in patients with upper gastrointestinal (GI) disease or in their disease animal model, suggesting its important role in the pathogenesis of upper GI disease.
Appetite/*physiology
;
Cysteamine/metabolism
;
Dyspepsia/etiology
;
*Eating
;
Gastrointestinal Diseases/*etiology
;
Ghrelin/*physiology
;
Humans
;
Peptic Ulcer/etiology
7.Does Bile Reflux Influence the Progression of Barrett's Esophagus to Adenocarcinoma? (Gastroenterology 2013;145:1300-1311).
Tatsuhiro MASAOKA ; Hidekazu SUZUKI
Journal of Neurogastroenterology and Motility 2014;20(1):124-126
No abstract available.
Adenocarcinoma*
;
Barrett Esophagus*
;
Bile Reflux*
;
Bile*
8.Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis.
Hidekazu SUZUKI ; Yoshimasa SAITO ; Toshifumi HIBI
Gut and Liver 2009;3(2):81-87
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
Adoption
;
Helicobacter
;
Helicobacter pylori
;
Humans
;
Lymphoid Tissue
;
Lymphoma
;
Lymphoma, B-Cell, Marginal Zone
9.Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.
Yasushi FUKUSHIMA ; Hidekazu SUZUKI ; Juntaro MATSUZAKI ; Arihiro KIYOSUE ; Toshifumi HIBI
Journal of Neurogastroenterology and Motility 2012;18(3):317-323
BACKGROUND/AIMS: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). METHODS: A total of 20 patients with IBS-D were enrolled. After a 2-week observation period, all participants received solifenacin for 6 weeks. Subsequently, the administration of solifenacin was discontinued and ramosetron, a serotonin 3 receptor antagonist, was administered for 4 weeks. Overall improvement, the IBS-symptom severity scale (IBS-SSS), and frequency of defecation were assessed. RESULTS: Six weeks after initiation of solifenacin treatment and 4 weeks after initiation of ramosetron treatment, overall improvement was observed in 19 out of 20 (95%) and 17 out of 20 (85%) participants, respectively. At 2 weeks after initiation of solifenacin, overall improvement was observed in 16 out of 20 participants (80%). Total IBS-SSS scores at 2 and 6 weeks after the administration of solifenacin, and at 4 weeks after administration of ramosetron, were significantly lower than those at week 0. Compared to before administration, the participants' quality of life and frequency of defecation were significantly lower in all participants at 2 and 6 weeks after the administration of solifenacin and at 4 weeks after administration of ramosetron. CONCLUSIONS: The efficacy of solifenacin in the treatment of IBS with diarrhea was not inferior to that of ramosetron. Further placebo-controlled parallel studies are needed.
Adult
;
Benzimidazoles
;
Defecation
;
Diarrhea
;
Humans
;
Irritable Bowel Syndrome
;
Prospective Studies
;
Quality of Life
;
Quinuclidines
;
Receptors, Serotonin, 5-HT3
;
Tetrahydroisoquinolines
;
Urinary Bladder
;
Urinary Bladder, Overactive
;
Solifenacin Succinate
10.Colonic dysmotility and morphological abnormality frequently detected in Japanese patients with irritable bowel syndrome.
Takeshi MIZUKAMI ; Shinya SUGIMOTO ; Tatsuhiro MASAOKA ; Hidekazu SUZUKI ; Takanori KANAI
Intestinal Research 2017;15(2):236-243
BACKGROUND/AIMS: Colonoscopy and computed tomography (CT) are used primarily to exclude organic diseases in patients with irritable bowel syndrome (IBS), rather than to assess the pathophysiology of IBS. We aimed to evaluate colonic dysmotility and morphology in Japanese patients with IBS. METHODS: One hundred eighty-four patients with IBS and 49 asymptomatic controls who underwent colonoscopy in combination with CT colonography or barium enema were retrospectively reviewed between 2008 and 2012. Water-aided colonoscopy was performed without sedation by a single endoscopist. The duration and pattern of colonic movement and cecal intubation time were recorded. To assess colonic morphology, barium enema or CT colonography were performed immediately after colonoscopy. RESULTS: Colonic dysmotility was more frequent in the IBS group (28.8% vs. 2.0% in controls, P<0.001), especially in cases of IBS with diarrhea (IBS-D) (IBS with constipation [IBS-C] 28.8% vs. IBS-D 60.0% vs. mixed IBS [IBS-M] 5.1%, P<0.001). Colonic morphological abnormality was more frequent in the IBS group than in the control group (77.7% vs. 24.5%, P<0.001), especially in IBS-M and IBS-C groups (IBS-C 77.5% vs. IBS-D 48.9% vs. IBS-M 100%, P<0.001). Most patients with IBS with colonic dysmotility had experienced stress related to their symptoms. Cecal intubation time was significantly longer in the IBS group than in the control group (12.1±6.9 minutes vs. 4.6±1.9 minutes, P<0.001). CONCLUSIONS: Unsedated colonoscopy, combined with radiographic findings, can detect colonic dysmotility and morphological abnormality. Technical difficulties observed during cecal intubation may partially explain the pathophysiology of IBS.
Asian Continental Ancestry Group*
;
Barium
;
Colon*
;
Colonography, Computed Tomographic
;
Colonoscopy
;
Constipation
;
Diarrhea
;
Enema
;
Humans
;
Intubation
;
Irritable Bowel Syndrome*
;
Radiography
;
Retrospective Studies